logo-loader
viewPhagelux

Phagelux looking to raise $20M for its Phase 1 and Phase 2 studies

Phagelux CEO Mark Engel sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The privately-held, China-based company utilizes phages to solve bacterial problems in multiple fields including crop diseases, animal health, food safety and general sanitary. 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks finish week in the red; Canaccord initiates...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was down 2.6% higher at 117.4 points. Elsewhere, the OTCQX Cannabis index fell 1.8% to 480.1 points. Buds today were Pharmacielo Ltd (CVE:PCLO), The Valens Company (CVE:VLNS) (OTCMKTS:VLNCF)....

1 day, 3 hours ago

2 min read